Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Developments Hematology Phase III
Sweden 
Details:
Treatment with pegcetacoplan resulted in a sustained improvement in haemoglobin with a mean increase from baseline of 2.7 g/dL at week 48, which is equal to the 2.7 g/dL increase seen at week 16 with pegcetacoplan-treated patients.
Lead Product(s): Pegcetacoplan
Therapeutic Area: Hematology Product Name: APL-2
Highest Development Status: Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Apellis Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2020
Details:
Though avatrombopag increased platelet counts relative to placebo as expected, the study did not meet the composite primary endpoint of avoiding platelet transfusions, chemotherapy dose reductions by 15 per cent or greater, and chemotherapy dose delays by four days or more.
Lead Product(s): Avatrombopag
Therapeutic Area: Hematology Product Name: Doptelet
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2020
